Both ELOVL1 and ELOVL6 are biomarkers associated with an increased risk of NAFLD in the HIV-negative population with metabolic syndrome [20,21]. The gene discussed is ELOVL6; the disease is metabolic dysfunction-associated steatotic liver disease.